New therapies for immune thrombocytopenic purpura

Current Opinion in Hematology

Volumn 14, Issue 5, 2007, Pages 427-431

  Andemariam, Biree ^a   Bussel, James ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

AMG531; Anti D immunoglobulin; Dexamethasone; Eltrombopag; Rituximab; Thrombopoiesis

Indexed keywords

AKR 501; AMG 531; CORTICOSTEROID; DEXAMETHASONE; ELTROMBOPAG; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; PLACEBO; PREDNISONE; RECOMBINANT PROTEIN; RHESUS D ANTIBODY; RITUXIMAB; STEROID; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR; UNCLASSIFIED DRUG;

BLEEDING; CHICKENPOX; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG INFUSION; DRUG MEGADOSE; HEADACHE; HUMAN; HYPOTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PANCREAS ISLET CELL TUMOR; PATIENT CARE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; SERUM SICKNESS; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPOIESIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; DEXAMETHASONE; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOCYTE DEPLETION; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RHO(D) IMMUNE GLOBULIN; THROMBOPOIESIS; THROMBOPOIETIN;

EID: 34648819059     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3282a4a68b     Document Type: Review

References (40)

1. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83:435-445.
2. Stasi R, Pagano A, Stipa E, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenia purpura. Blood 2001; 98:952-957.
3. Giagounidis AA, Anhuf J, Schneider P, et al. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. Eur J Haematol 2002; 69:95-100.
4. Wang J, Wiley JM, Luddy R, et al. Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. J Pediatr 2005; 146:217-221.
5. Bennett CM, Rogers ZR, Dinnamon DD, et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 2006; 107:2639-2642. This is the first published trial of rituximab therapy for severe chronic ITP in a pediatric population. This paper is also the first to report rituximab pharmacokinetic data in children.
6. Penalver FJ, Jinenez-Yuste V, Almagro M, et al. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and sage therapeutic alternative in refractory patients. Ann Hematol 2006; 85:400-406. This retrospective analysis found significantly better overall responses to rituximab in patients who had not undergone splenectomy, were less heavily pretreated and had a shorter duration of ITP.
7. Godeau B, Fain O, Porcher R, et al. Rituximab is an alternative to splenectomy in adults with chronic immune thrombocytopenic purpura: results of a multicenter prospective phase 2 study. Blood 2006; 108:478a.
8. Taube T, Schmid H, Reinhard H, et al. Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood. Haematologica 2005; 90:281-283.
9. Tanaka E, Hayashi S, Fujimaki K, et al. Single dose of anti-CD20 monoclonal antibody (Rituximab) treatment in adults with refractory immune thrombocytopenic purpura. Blood 2006; 108:1077a.
10. Patel V, Mihatov N, Cooper N, et al. Long term follow-up of patients with immune thrombocytopenic purpura (ITP) whose initial response to rituximab lasted a minimum of one year. Blood 2006; 108:479a.
11. Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007; 146:25-33.
12. Broudy VC, Lin HL. AMG 531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine 2004; 25:52-60.
13. Nomura S, Dan K, Hotta T, et al. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood 2002; 100:728-730.
14. Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98:3241-3248.
15. Basser RL, O'Flaherty E, Green M, et al. Development of panctyopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 2002; 99:2599-2602.
16. Hartley C, McElroy T, Molineux G, et al. The novel thrombopoietic agent AMG 531 is effective in preclinical models of chemo/radiotherapy induced thrombocytopenia. Proc Am Assoc Cancer Res 2005; 46:1233.
17. Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004; 76:628-638.
18. Schiffer CA, Miller K, Larson RA, et al. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood 2000; 95:2530-2535.
19. Newland A, Caulier MT, Kapper-Klunne M, et al. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol 2006; 135:547-553. This phase 1/2 study established the safety and tolerability of subcutaneous AMG531. Efficacy was highest in patients with dose equivalents of >1 μg/kg.
20. Bussel JB, Kuter DH, George JN, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006; 355:1672-1681. This phase 1/2 randomized, placebo-controlled clinical trial demonstrated that extended weekly dosing of AMG531 is tolerable and capable of producing sustained platelet responses.
21. Kuter D, Bussel J, George J, et al. Long-term dosing of AMG 531 in thrombocytopenic patients with immune thrombocytopenic purpura: 48-week update. Blood 2006; 108:476a.
22. George JN, Bussel JB, McMillan R, et al. Analysis of health-related quality of life in patients receiving AMG 531 using the disease-specific immune thrombocytopenic purpura patient assessment questionnaire. Blood 2006; 108:3292a.
23. Aledort LM, Lyons RM, Okano G, Leveque J. Retrospective matched cohort study of immune thrombocytopenic purpura (ITP): complications related to corticosteroid (CS) use. Blood 2006; 108:3295a. This retrospective claims analysis on over 40 000 corticosteroid users clearly identifies a dose-response relationship to corticosteroid use in ITP patients and the development of serious complications.
24. Andersen JC. Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. N Engl J Med 1994; 330:1560-1564.
25. Cheng Y, Wong RS, Soo YO, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med 2003; 349:831-836.
26. Mazzucconi MG, Fazi P, Bernasconi S, et al. Therapy with high-dose (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood 2007; 109:1401-1407. This multicenter prospective study confirms the findings of Andersen [24] and Cheng et al. [25] that initial therapy with high-dose dexamethasone in ITP patients is efficacious. The GIMEMA findings suggest that at least three cycles of therapy are necessary for response durability.
27. Beardsley DS. Oral dexamethasone therapy for chronic immune thrombocytopenic purpura: home run or base hit? J Pediatr 1997; 130:1-2.
28. Salama A, Kiefel V, Amberg R, Mueller-Eckhardt C. Treatment of autoimmune thrombocytopenic purpura with rhesus antibodies [anti-Rh0 (D)]. Blut 1984; 49:29-35.
29. Blanchette C, Imbach P, Andrew M, et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 1994; 344:703-707.
30. El Alfy MS, Mokhtar GM, El-Laboudy MA, et al. Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura. Acta Haematol 2006; 115:46-52.
31. Newman GC, Novoa MV, Fodero EM, et al. A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura. Br J Haematol 2001; 112:1076-1078.
32. Gaines AR. Acute onset hemoglobinemia and/or hemoglobinuria and sequelae following Rh(0)(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients. Blood 2000; 95:2523-2529.
33. Gaines AR. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0)(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood 2005; 106:1532-1537.
34. Roberti I, Bagtas JF, Reisman L, et al. Severe acute renal failure due to hemoglobinuria after use of WinRho for the treatment of idiopathic thrombocytopenic purpura. Clin Pediatr (Phila) 2001; 40:61-62.
35. Wetzel DA, Tarantino MD. Cost-minimization analysis of anti-D immune globulin versus intravenous immune globulin for the initial treatment of immune thrombocytopenic purpura. Blood 2006; 108:3305a.
36. Meyer O, Kiesewetter H, Hermsen M, et al. Replacement of intravenous administration of anti-D by subcutaneous administration in patients with autoimmune thrombocytopenia. Pediatr Blood Cancer 2006; 47: 721-722.
37. Tarantino MD, Young G, Bertolone SJ, et al. Single dose of anti-D immune globulin at 75ug/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children. J Pediatr 2006; 148:489-494. This randomized study in children demonstrates head to head that intravenous anti-D immunoglobulin (at doses of 75 μg/kg) is as effective as high-dose IVIg, confirming the 2001 study by Newman et al. [31] in adults.
38. Jenkins JM, Williams D, Deng Y, et al. Phase I clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007; 109:4739-4741. This is the first report (in normal volunteers) of the use, including dosing, of eltrombopag.
39. Bussel JB, Cheng G, Saleh M, et al. Analysis of bleeding in patients with immune thrombocytopenicpurpura (ITP):a randomized,double-blind, placebo-controlled trial of eltrombopag, an oral platelet growth factor. Blood 2006; 108:475a.
40. Desjardins RE, Tempel DL, Lucek R, Kuter DJ. Single and multiple oral doses of AKR-501 (YM477) increase the platelet count in healthy volunteers. Blood 2006; 108:477a.